glp-1 pancreatitis risk There has been a drug safety update from Medicines and Healthcare products Regulatory Agency (MHRA) for healthcare professionals GLP-1 Pancreatitis Risk: MHRA Warning

The treatment given to this patient resulted in an improved microbiome with an increase in bacterial diversity, partly due to an increase in the relative abundance of butyrate-producing bacterial species, which were paralleled by an increase in butyrate concentration, an anti-inflammatory SCFA (Engen et al., 2020)

CV, Cardiovascular

Further investigations are needed to comprehensively assess the functional and safety aspects of long-term Exe4 secretion

Wegovy (semaglutide) was only recently approved by the FDA for weight management in individuals with obesity or overweight, weight gain, and at least one weight-related health condition